AMPH250417C22500
- 0.00
- 0.000.00%
Amphastar Pharmaceuticals Newsroom
Trump Says 'Major Tariff on Pharmaceuticals' Coming Soon
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Insider Sale: Director at $AMPH Sells 500 Shares
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Amphastar Pharmaceuticals Is Maintained at Neutral by Piper Sandler
Amphastar Pharma Analyst Ratings
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $32
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
New York Manufacturing Hits Low, Inflation Fears Rise
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
Amphastar Pharmaceuticals | 10-K: FY2024 Annual Report
A Quick Look at Today's Ratings for Amphastar Pharmaceuticals(AMPH.US), With a Forecast Between $36 to $40
Amphastar Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Small Cap Pharma Stocks to Buy Now?
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Maintains Target Price $36